Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia

2007 ◽  
Vol 32 (4) ◽  
pp. 385-391 ◽  
Author(s):  
Young-Hoon Ko ◽  
Sung-Won Jung ◽  
Sook-Haeng Joe ◽  
Chang-Hyun Lee ◽  
Hyun-Gang Jung ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Serum Testosterone ◽  
Chronic Schizophrenia ◽  
Testosterone Levels ◽  
Male Patients

Akathisia: Prevalence and Associated Dysphoria in an In-patient Population with Chronic Schizophrenia

1994 ◽  
Vol 164 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Simon M. Halstead ◽  
Thomas R. E. Barnes ◽  
Jeremy C. Speller
Keyword(s):  
Tardive Dyskinesia ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Significant Relation ◽  
Orofacial Dyskinesia ◽  
Increased Risk ◽  
Depot Antipsychotic ◽  
Male Patients ◽  
Higher Doses ◽  
Dysphoric Mood

In a sample of 120 long-stay in-patients who fulfilled DSM–III–R criteria for schizophrenia, chronic akathisia and pseudoakathisia were relatively common, with prevalence figures of 24% and 18%, respectively. Compared with patients without evidence of chronic akathisia, those patients with the condition were significantly younger, were receiving significantly higher doses of antipsychotic medication, and were more likely to be receiving a depot antipsychotic. Patients who experienced the characteristic inner restlessness and compulsion to move of akathisia also reported marked symptoms of dysphoria, namely tension, panic, irritability and impatience. The findings support the suggestion that dysphoric mood is an important feature of akathisia. Male patients appeared to be at an increased risk of pseudoakathisia. No significant relation was found between chronic akathisia and tardive dyskinesia, although there was a trend for trunk and limb dyskinesia to be commonest in patients with chronic akathisia while orofacial dyskinesia was most frequently observed in those with pseudoakathisia. Akathisia may mask the movements of tardive dyskinesia in the lower limb. There was no evidence that akathisia was associated with positive or negative symptoms of schizophrenia nor with depression.

scholarly journals mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia

2020 ◽  
Vol 41 (10) ◽  
pp. 2762-2781 ◽  
Author(s):  
Cláudia Régio Brambilla ◽  
Tanja Veselinović ◽  
Ravichandran Rajkumar ◽  
Jörg Mauler ◽  
Linda Orth ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Male Patients

Tardive Dyskinesia and Type II Schizophrenia

1992 ◽  
Vol 160 (2) ◽  
pp. 253-256 ◽  
Author(s):  
Elizabeth J. B. Davis ◽  
Milind Borde ◽  
L. N. Sharma
Keyword(s):  
Cognitive Impairment ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Thought Disorder ◽  
Control Group ◽  
Positive Symptoms ◽  
Type Ii ◽  
Formal Thought Disorder ◽  
Schizophrenic Patients ◽  
Male Patients

Cognitive impairment, negative and positive symptoms, primitive release reflexes, and age/temporal disorientation were assessed in 20 male patients meeting the DSM–III–R criteria for chronic schizophrenia and Schooler & Kane's criteria for TD. The control group comprised 20 age-matched male chronic schizophrenic patients without TD. Significant associations were found between TD, cognitive impairment, some negative symptoms, and formal thought disorder. These associations were independent of other illness and treatment variables. The severity of TD correlated significantly with that of cognitive impairment.

scholarly journals Brain-Derived Neurotropic Factor Serum Level and Severity Symptom of Bataknese Male Patients with Schizophrenia in North Sumatera, Indonesia

2019 ◽  
Vol 7 (12) ◽  
pp. 1957-1961
Author(s):  
Deasy Hendriati ◽  
Elemeida Effendy ◽  
Mustafa Mahfud Amin ◽  
Vita Camellia ◽  
Muhammad Surya Husada
Keyword(s):  
Serum Level ◽  
Negative Correlation ◽  
Symptom Severity ◽  
Negative Symptoms ◽  
Chronic Schizophrenia ◽  
Serum Levels ◽  
Cross Sectional ◽  
Syndrome Scale ◽  
Male Patients ◽  
Negative Syndrome

BACKGROUND: Schizophrenia is a severe mental disorder that is multi-causative and multi-factor, generally affecting about 1% of the population. The elevation level of brain-derived neurotrophic factor (BDNF) offers several protections from other neurodegenerative processes that occur in schizophrenia since this deficit of neurotrophic factors can contribute to changes in brain structure and function that underlie the schizophrenia psychopathology.AIM: To analyse the correlation between BDNF serum levels and symptom severity by using the Positive and Negative Syndrome Scale (PANSS) instrument in Bataknese male patients with schizophreniaMETHODS: This study was a correlative analytical study with a cross-sectional approach using the Positive and Negative Syndrome Scale (PANSS) instrument to assess symptom severity with 60 subjects of Bataknese male patients with chronic schizophrenia. Moreover, this research was conducted at the Psychiatric Hospital of Prof. Dr M. Ildrem Medan, Indonesia. BDNF serum was analysed with the Quantitative sandwich enzyme immunoassay technique by via Quantikine ELISA Human CXCL8/IL-8 HS. Also, the data analysis was performed through Spearman's correlative bivariate analytics using SPSS software.RESULTS: A negative correlation between the BDNF serum level and the negative scale PANSS score in men with schizophrenia (r = -0.820, p < 0.001) was found. Moreover, there is a negative correlation between BDNF serum levels and PANSS total scores in men with schizophrenia (r = -0.648, p < 0.001)CONCLUSION: BDNF serum level in Bataknese male patients with schizophrenia has a relationship that affects the severity of symptoms in schizophrenic patients, especially for negative symptoms.

scholarly journals Recovery of Serum Testosterone Levels is an Accurate Predictor of Survival From COVID-19 in Male Patients

2021 ◽  
Author(s):  
Emily Toscano ◽  
Mónica Martínez Gallo ◽  
Iria Arrese-Muñoz ◽  
Anna Giné ◽  
Noelia Díaz-Troyano ◽  
...  
Keyword(s):  
Serum Testosterone ◽  
Accurate Predictor ◽  
Testosterone Levels ◽  
Male Patients

scholarly journals Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients

2021 ◽  
Author(s):  
Emily Toscano-Guerra ◽  
Monica Martinez-Gallo ◽  
Iria Arrese-Munoz ◽  
Anna Gine ◽  
Noelia Diaz ◽  
...  
Keyword(s):  
Severe Disease ◽  
Strong Association ◽  
Serum Testosterone ◽  
Blood Levels ◽  
Testosterone Levels ◽  
Precise Knowledge ◽  
Male Patients ◽  
Male Sex ◽  
Classical Monocytes

Infection with SARS-CoV-2 portends a broad range of outcomes, from a majority of asymptomatic cases or mild clinical courses to a lethal disease. Robust correlates of severe COVID-19 include old age, male sex, poverty and co-morbidities such as obesity, diabetes or cardiovascular disease. A precise knowledge is still lacking of the molecular and biological mechanisms that may explain the association of severe disease with male sex. Here, we show that testosterone trajectories are highly accurate individual predictors (AUC of ROC = 0.928, p < 0.0001) of survival in male COVID-19 patients. Longitudinal determinations of blood levels of luteinizing hormone (LH) and androstenedione suggest an early modest inhibition of the central LH-androgen biosynthesis axis in a majority of patients, followed by either full recovery in survivors or a peripheral failure in lethal cases. Moreover, failure to reinstate physiological testosterone levels was associated with evidence of impaired T helper differentiation and decrease of non-classical monocytes. The strong association of recovery or failure to reinstate testosterone levels with survival or death from COVID-19 in male patients is suggestive of a significant role of testosterone status in the immune responses to COVID-19.

scholarly journals Serum testosterone levels and clinical signs of hypogonadism in men with type 2 diabetes

2021 ◽  
Vol 8 (8) ◽  
pp. 3777
Author(s):  
Manouchehr Iranparvar ◽  
Firouz Amani ◽  
Md. Javad Naghizadeh
Keyword(s):  
Clinical Signs ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Testosterone Levels ◽  
Drug History ◽  
Male Patients ◽  
Age Range

Background: Diabetes mellitus is a common metabolic disease that its association with low level of testosterone has already been shown in many studies. Considering the role of testosterone hormone in impotency, fatigue, and bone mass deficiency this study aimed to evaluate the total and free testosterone levels and clinical signs of hypogonadism in male patients with type 2 diabetes.Methods: In this descriptive-cross sectional study, sixty-five diabetic male patients aged 35-70 years were randomly selected and enrolled to the study. The necessary information such as patient demographics, BMI, past medical history, drug history, and history of smoking, education level and employment were completed by a checklist. Then, the patients were evaluated for total and free testosterone levels and symptoms related to decreased testosterone, hypogonadism symptoms by ADAM questionnaire. Finally, the data were statistical analyzed by spss version 21.Results: The mean age of patients was 57.12±4.7 years with age range of 38-69 years. According to the ADAM questionnaire, 51 (78.4%) of the patients were positive and 14 (21.6%) were negative. 16 (24.6%) of all patients had hypogonadism. Among ADAM positive patients, 46 (90.1%) had erectile dysfunction and 33 (64.7%) had decreased libido. Most people (75%) with hypogonadism had BMI more than 30.Conclusions: Testosterone levels are commonly found low in diabetic men, most of whom have symptoms of hypogonadism. Body mass index is known as an independent risk factor for hypogonadism in T2D men. There was also a significant correlation between free testosterone levels and hypogonadism. 

Sign in / Sign up

Export Citation Format

Share Document